Diadem is an innovative blood-based test exploiting a proprietary antibody targeting a specific conformation of p53 protein.
Diadem has raised $2.5M in total funding. The most recent round was Grant. The last funding was announced in September 2022.
Diadem's investors include European Investment Bank, CDP Venture Capital, Panakes Partners, National Institute on Aging.
Diadem is headquartered in Brescia, Italy.
Diadem is an innovative blood-based test exploiting a proprietary antibody targeting a specific conformation of p53 protein.
Diadem is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Diadem — Funding & Investors." VCBacked, September 7, 2022, https://www.vcbacked.co/company/diadem. Accessed July 20, 2026.
VCBacked. (2022). Diadem — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/diadem
{{cite web |title=Diadem — Funding & Investors |url=https://www.vcbacked.co/company/diadem |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated